Enanta Pharmaceuticals Inc (ENTA)vsRoyalty Pharma Plc (RPRX)
ENTA
Enanta Pharmaceuticals Inc
$11.28
-3.84%
HEALTHCARE · Cap: $328.00M
RPRX
Royalty Pharma Plc
$55.02
-1.09%
HEALTHCARE · Cap: $31.60B
Smart Verdict
WallStSmart Research — data-driven comparison
Royalty Pharma Plc generates 3426% more annual revenue ($2.44B vs $69.21M). RPRX leads profitability with a 33.9% profit margin vs -89.6%. RPRX earns a higher WallStSmart Score of 65/100 (C+).
ENTA
Avoid30
out of 100
Grade: F
RPRX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+41.4%
Fair Value
$24.33
Current Price
$11.28
$13.05 discount
Margin of Safety
-59.6%
Fair Value
$34.38
Current Price
$55.02
$20.64 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
15.0% revenue growth
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Areas to Watch
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
ROE of -53.2% — below average capital efficiency
Expensive relative to growth rate
Moderate valuation
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ENTA
The strongest argument for ENTA centers on Price/Book, Revenue Growth. Revenue growth of 15.0% demonstrates continued momentum.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : ENTA
The primary concerns for ENTA are Market Cap, Debt/Equity, Piotroski F-Score. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
ENTA profiles as a turnaround stock while RPRX is a mature play — different risk/reward profiles.
ENTA carries more volatility with a beta of 0.99 — expect wider price swings.
ENTA is growing revenue faster at 15.0% — sustainability is the question.
RPRX generates stronger free cash flow (761M), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (65/100 vs 30/100), backed by strong 33.9% margins and 11.0% revenue growth. ENTA offers better value entry with a 41.4% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Enanta Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?